[ad_1]
The specifics of these practices are unclear, although insurance companies such as Aetna, Anthem and Regence Blue Cross Blue Shield are also looking at billing patterns of late. ubiome. An unidentified member of the insurance industry told the WSJ uBiome had billed patients benefiting from Medicare private plans, while a client complained to the California Medical Board after doctors approved tests based on an ubiome checklist without the contact directly.
Company director Jessica Richman (pictured above) said the company did not charge government customers. In a statement, uBiome said it did not have control over the billing of doctors and that any "inappropriate" billing was not related to its own practices. It was "fully cooperating" with federal officials.
Unlike Theranos, the science and technology behind uBiome seem to be healthy. Although the utility of microbiome data is not yet clear, DNA sequencing tests such as SmartGut's ubiome should at least provide accurate data. However, it is easy to understand why society could be closely watched. Medical technology startups like this one are under intense regulatory pressure, and the sordid history of Theranos gives managers another reason to take a closer look at it.
Source link
